Form 4: Enliven COO Sells Shares Under Pre-Arranged 10b5-1 Plan

Enliven Therapeutics' Chief Operating Officer, Anish Patel, sold 6,667 shares of common stock for $20.2426 per share on September 8, 2025, under a pre-arranged trading plan.

Summary

• Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (ELVN), reported a sale of common stock.
• The transaction involved the disposition of 6,667 shares of common stock.
• The shares were sold at a weighted average price of $20.2426 per share.
• The sale was executed on September 8, 2025.
• This transaction was conducted pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024.
• Following the transaction, Anish Patel beneficially owns 283,308 shares indirectly through The Patel / Dong Family Trust.

Sentiment

Score: 5

Explanation: The sale by a Chief Operating Officer, while executed under a pre-arranged 10b5-1 plan, represents a reduction in insider holdings. However, the pre-planned nature mitigates negative sentiment, making it a neutral to slightly negative event.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction for personal financial management rather than a discretionary sale based on new material non-public information.

Negatives

• Chief Operating Officer Anish Patel sold 6,667 shares of company common stock, reducing insider ownership.
• The transaction occurred at a weighted average price of $20.2426 per share.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• The shares sold were held by The Patel / Dong Family Trust, for which Anish Patel serves as trustee, indicating a related party transaction.

Stakeholder Impact

• Shareholders may perceive the insider sale as a slight reduction in management's direct equity interest, though the pre-planned nature under a 10b5-1 plan suggests it is for personal financial management rather than a reaction to company performance.

Key Dates

Keywords

Enliven Therapeutics, ELVN, Anish Patel, insider trading, Form 4, stock sale, 10b5-1 plan, officer transaction